Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma

[1]  R. Davis,et al.  Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. , 2017, Blood.

[2]  Wei Zhang,et al.  PIK3CA amplification and PTEN loss in diffused large B-cell lymphoma , 2017, Oncotarget.

[3]  K. Dybkær,et al.  AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. , 2017, The American journal of pathology.

[4]  G. Ott,et al.  Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. , 2017, Blood.

[5]  F. Slack,et al.  MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs , 2017, Leukemia.

[6]  Meng-Lay Lin,et al.  The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1 , 2017, Oncotarget.

[7]  Michael L. Wang,et al.  Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. , 2016, Blood.

[8]  Gui-yuan Li,et al.  MiR-200c is a cMyc-activated miRNA that promotes nasopharyngeal carcinoma by downregulating PTEN , 2016, Oncotarget.

[9]  S. Ikeda,et al.  Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors. , 2016, JAMA oncology.

[10]  L. Pasqualucci,et al.  Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma , 2016, Leukemia.

[11]  S. Shen-Orr,et al.  A c-Myc/miR17-92/Pten Axis Controls PI3K-Mediated Positive and Negative Selection in B Cell Development and Reconstitutes CD19 Deficiency. , 2016, Cell reports.

[12]  B. Blencowe,et al.  IGF2BP3 Modulates the Interaction of Invasion-Associated Transcripts with RISC. , 2016, Cell reports.

[13]  T. Graeber,et al.  PTEN opposes negative selection and enables oncogenic transformation of pre-B cells , 2016, Nature Medicine.

[14]  W. Choi,et al.  p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function , 2016, Aging.

[15]  J. McQuade,et al.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.

[16]  A. Hague,et al.  The PI3K/Akt Pathway in Tumors of Endocrine Tissues , 2016, Front. Endocrinol..

[17]  W. Choi,et al.  Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP , 2015, Modern Pathology.

[18]  K. Young,et al.  The PTEN tumor suppressor gene and its role in lymphoma pathogenesis , 2015, Aging.

[19]  K. Akashi,et al.  Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. , 2015, Blood.

[20]  Yihui Ma,et al.  Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL. , 2015, International journal of clinical and experimental pathology.

[21]  W. Choi,et al.  Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy , 2015, Modern Pathology.

[22]  A. Janin,et al.  The High Expression of the microRNA 17-92 Cluster and its Paralogs, and the Downregulation of the Target Gene PTEN, Is Associated with Primary Cutaneous B-Cell Lymphoma Progression. , 2015, The Journal of investigative dermatology.

[23]  P. Pinton,et al.  Study of PTEN subcellular localization , 2015, Methods.

[24]  L. Staudt,et al.  B-cell receptor signaling in diffuse large B-cell lymphoma. , 2015, Seminars in hematology.

[25]  Felipe D’Almeida Costa,et al.  Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab , 2015, International Journal of Clinical Oncology.

[26]  M. Mraz,et al.  B‐cell receptor signalling and its crosstalk with other pathways in normal and malignant cells , 2015, European journal of haematology.

[27]  William L. Welbourn,et al.  PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer , 2014, International journal of urology : official journal of the Japanese Urological Association.

[28]  P. Fox,et al.  Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations , 2014, Clinical Cancer Research.

[29]  W. Choi,et al.  Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma , 2014, Clinical Cancer Research.

[30]  A. Navarro,et al.  miR-141 and miR-200c as Markers of Overall Survival in Early Stage Non-Small Cell Lung Cancer Adenocarcinoma , 2014, PloS one.

[31]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[32]  D. Hua,et al.  MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. , 2014, Human immunology.

[33]  S. Teo,et al.  Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer. , 2014, American journal of clinical pathology.

[34]  W. Choi,et al.  MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.

[35]  G. Lenz,et al.  PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[36]  V. Boussiotis,et al.  PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2 , 2013, Molecular and Cellular Biology.

[37]  M. Cole,et al.  Molecular and Cellular Pathobiology Myc Acts via the Pten Tumor Suppressor to Elicit Autoregulation and Genome-wide Gene Repression by Activation of the Ezh2 Methyltransferase , 2022 .

[38]  W. Choi,et al.  Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.

[39]  K. Dybkær,et al.  Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2012, Leukemia.

[40]  K. Hoang-Xuan,et al.  Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas , 2012, Clinical Cancer Research.

[41]  K. Black,et al.  Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era , 2012, PloS one.

[42]  M. Davies.  Regulation, role, and targeting of Akt in cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  K. Thennarasu,et al.  Homozygous 10q23/PTEN deletion and its impact on outcome in glioblastoma: A prospective translational study on a uniformly treated cohort of adult patients , 2011, Neuropathology : official journal of the Japanese Society of Neuropathology.

[44]  N. Schmitz,et al.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  K. Fu,et al.  PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma , 2010, Leukemia & lymphoma.

[46]  H. Nilsson‐Ehle,et al.  High immunohistochemical expression of p‐AKT predicts inferior survival in patients with diffuse large B‐cell lymphoma treated with immunochemotherapy , 2010, British journal of haematology.

[47]  Hansjuerg Alder,et al.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. , 2009, Cancer cell.

[48]  P. Pandolfi,et al.  BCR-mediated apoptosis associated with negative selection of immature B cells is selectively dependent on Pten , 2009, Cell Research.

[49]  T. Mak,et al.  PTEN Deletion and Concomitant c-Myc Activation Do Not Lead to Tumor Formation in Pancreatic β Cells* , 2009, Journal of Biological Chemistry.

[50]  Robert Tibshirani,et al.  Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. , 2008, Blood.

[51]  Nobuo Ochi,et al.  Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival , 2008, BMC gastroenterology.

[52]  K. Nielsen,et al.  Is PTEN loss associated with clinical outcome measures in human prostate cancer? , 2008, British Journal of Cancer.

[53]  Y. Yin,et al.  PTEN: a new guardian of the genome , 2008, Oncogene.

[54]  L. Staudt,et al.  Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.

[55]  A. Sabichi,et al.  Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray , 2008, Molecular carcinogenesis.

[56]  W. Sellers,et al.  PTEN Nuclear Localization Is Regulated by Oxidative Stress and Mediates p53-Dependent Tumor Suppression , 2008, Molecular and Cellular Biology.

[57]  A. Gericke,et al.  PTEN phosphatase selectively binds phosphoinositides and undergoes structural changes. , 2008, Biochemistry.

[58]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[59]  A. Levine,et al.  The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. , 2007, Cancer research.

[60]  A. Andres-Pons,et al.  Nuclear PTEN: a tale of many tails , 2007, Cell Death and Differentiation.

[61]  Tom Misteli,et al.  Ubiquitination Regulates PTEN Nuclear Import and Tumor Suppression , 2007, Cell.

[62]  P. Pandolfi,et al.  Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity , 2007, Cell.

[63]  T. Mustelin,et al.  Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC-β II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN , 2007, Leukemia & lymphoma.

[64]  Jing Wang,et al.  PQN and DQN: algorithms for expression microarrays. , 2006, Journal of theoretical biology.

[65]  K. Al-Kuraya,et al.  Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. , 2005, Blood.

[66]  V. A. Flørenes,et al.  Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. , 2005, American journal of clinical pathology.

[67]  R. Gascoyne,et al.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  C. Eng,et al.  Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. , 2005, Cancer research.

[69]  A. Newton,et al.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.

[70]  S. Pinder,et al.  The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome , 2004, The Journal of pathology.

[71]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[72]  T. Mak,et al.  Critical Roles of Pten in B Cell Homeostasis and Immunoglobulin Class Switch Recombination , 2003, The Journal of experimental medicine.

[73]  M. Tachibana,et al.  Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma , 2002, Cancer.

[74]  William R. Sellers,et al.  Phosphorylation of the PTEN Tail Acts as an Inhibitory Switch by Preventing Its Recruitment into a Protein Complex* , 2001, The Journal of Biological Chemistry.

[75]  T. Mak,et al.  Regulation of PTEN transcription by p53. , 2001, Molecular cell.

[76]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[77]  Tomohiko Maehama,et al.  Crystal Structure of the PTEN Tumor Suppressor Implications for Its Phosphoinositide Phosphatase Activity and Membrane Association , 1999, Cell.

[78]  R. Ray,et al.  PTEN transcriptionally modulates c-myc gene expression in human breast carcinoma cells and is involved in cell growth regulation. , 1999, Gene.

[79]  J. Herman,et al.  Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers , 1998, Oncogene.

[80]  M. Ittmann,et al.  Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[81]  J. Bruce,et al.  Somatic mutations of PTEN in glioblastoma multiforme. , 1997, Cancer research.

[82]  Kathleen R. Cho,et al.  Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. , 1997, Cancer research.

[83]  S. Shen-Orr,et al.  A c-Myc / miR 1792 / Pten A xis Controls PI 3 K-Mediated Positive and Negative Selection in B Cell Development and Reconstitutes CD 19 Deficiency Graphical , 2016 .

[84]  Yong,et al.  Assessment of CD 37 B-cell antigen and cell-of-origin significantly improves risk prediction in diffuse large B-cell lymphoma , 2016 .

[85]  F. Slack,et al.  MUC 1 Inhibition Leads to Decrease in PD-L 1 Levels via Up-Regulation of miRNAs , 2016 .

[86]  K. Dybkær,et al.  Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2014, Leukemia.

[87]  S. Rho,et al.  Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. , 2012, Cellular signalling.

[88]  P. Mischel,et al.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.

[89]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[90]  M. Raffeld,et al.  PTEN gene alterations in lymphoid neoplasms. , 1998, Blood.